Strong evidence for informed and timely decisions for the benefit of all patients

The upcoming proposal by the European Commission on the revision of the EU general pharmaceuticals legislation, expected by the end of 2022, intends to address shortcomings in terms of access to and availability of new treatments. Safety, quality and affordability are crucial elements for bringing effective medicines to the market with significant benefits for patients and healthcare systems’ sustainability.

The European Social Insurance Platform (ESIP) and the Medicines Evaluation Committee (MEDEV) – the leading voice of statutory healthcare payers across Europe – present a list of detailed amendments to the legal texts - Regulation 726/2004 and Directive 2003/81/EU.

To learn more about our proposals from our experts, make sure to join the ESIP-MEDEV webinar on Wednesday 6 July at 11 am CET.